64 results about "Chalcone" patented technology

The present application relates to a kind of catalyst composition and its application in catalytic preparation optically active secondary alcohol, the catalyst composition includes chiral ionic bridged aryloxyalkane rare earth complex and additive, the additive is selected from one or more of pyrimidine, N,N-dicyclohexylmethylamine, 4,4'-dipyridyl.The above-mentioned catalyst composition can be used for synergistically catalyzing asymmetric borohydration of chalcone and its derivatives with pinacol borane, and show high catalytic activity and high enantioselectivity, product yield is as high as 99%, ee value can reach 84%, provide a reliable new way for the efficient, high selective synthesis of optically active secondary alcohol.

The invention relates to a surface-imprinted combined modified electrode and its production method, comprising a novel chalcone-substituted cyclotriphosphazene (CBRG-Fe) and multi-walled carbon nanotube (MWCNT) composite, intended to be used as an electrochemically active sensor for the sensitive determination of ractopamine.

This invention provides a chalcone isopentenyltransferase gene. GiPT16 This invention relates to the GiPT16 protein, amplification primer set, and applications, belonging to the field of biogenetics technology. It is based on *Glycyrrhiza inflata* (GiPT16 protein, amplification primer set, and applications). Glycyrrhiza inflata Using whole-genome sequencing data and a reverse genetics strategy, the key aromatic isopentenyltransferase GiPT16, involved in the isopentenylation modification of chalcone active ingredients, was successfully identified and functionally characterized. This enzyme was confirmed to specifically catalyze the biosynthesis of psoralen and glycyrrhizin C using DMAPP as a donor. It is the first chalcone isopentenyltransferase characterized in *Glycyrrhiza inflata*, filling a gap in the study of key enzymes in the chalcone isopentenylation metabolic pathway of this species and providing important evidence for further elucidating the molecular mechanisms of quality formation in *Glycyrrhiza inflata* medicinal materials.

The invention discloses an indole pyridine chalcone compound and application thereof in medicine for treating colitis, and belongs to the technical field of biological medicine. The compound has a structure as shown in a formula I, wherein R1 is selected from C1-C8 alkyl, C1-C8 alkoxy, halogen, cyano, nitryl and morpholinyl, and R2 is selected from nitryl. According to the invention, multiple excellent pharmacophores such as indole, pyridine, chalcone, sulfonamide and the like are fused in the same molecule for the first time, the preparation method does not need pre-activation of a substrate, does not need a metal catalyst or an additive, and has the advantages of mild reaction conditions, high yield, good selectivity, low cost and environmental friendliness. The compound has strong inhibitory activity on hexokinase 2 (HK2), can significantly inhibit inflammatory response and regulate macrophage polarization, shows an excellent colitis treatment effect in in-vivo and in-vitro experiments, provides a new choice for developing novel colitis treatment drugs, and has a wide medical application prospect.

The application discloses a hydroxyl chalcone carboxyl derivative and a preparation method thereof, and provides use of the compound, a pharmaceutically acceptable salt thereof or a mixture thereof in preparation of a medicine for preventing and / or treating diabetes and complications thereof. The compound is used as an aldose reductase selective inhibitor, an alpha-glucosidase inhibitor, a hypoglycemic agent, an antioxidant and a lipid metabolism improver, and has the effects of preventing and / or treating diabetes and complications thereof. The application further provides a pharmaceutical composition containing the compound and having the effects of preventing and / or treating diabetes and complications thereof. In the application, R1 is a hydroxyl group or an alkoxy group, the alkoxy group is preferably a methoxy group or an ethoxy group; R2, R3, R4, R5 and R6 are independently selected from hydrogen, halogen, a hydroxyl group, a methoxy group or a trifluoromethyl group, and at least one of R2, R3, R4, R5 and R6 is a hydroxyl group; and the halogen is preferably fluorine.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

To provide a chalcone dye compound that can be produced from living cells of Escherichia coli and has high industrial utility, and means and methods for the production of the same.SOLUTION: The present invention provides a composition for producing a chalcone dye compound which is a glycoside of isoliquiritigenin with a methylated hydroxy group at 2' position, the composition comprising cells of Escherichia coli expressing 4-coumarate-CoA ligase (4CL), chalcone synthase (CHS), chalcone reductase (CHR), isoliquiritigenin 2'-O-methyltransferase (I2'MT), and UDP glycosyltransferase (UGT). There are also provided a chalcone dye compound and a method for producing the same.SELECTED DRAWING: Figure 3

The invention discloses a chalcone substituted compound, a preparation method thereof and application of the chalcone substituted compound in preparation of anti-inflammatory drugs, and relates to the field of medicinal chemistry. In particular relates to chalcone substituted compounds, a preparation method thereof, a pharmaceutical composition containing the compounds and medical application thereof, and particularly, the chalcone substituted compounds can remarkably inhibit generation of inflammatory mediators and have important application potential and clinical value in treatment of inflammation-related diseases. Based on the molecular hybridization principle, the chalcone substituted compound is prepared through a chemical synthesis method, and experiments show that the compound has remarkable advantages in the aspect of inhibiting generation of inflammatory mediators (such as NO) and has the application potential of developing novel anti-inflammatory drugs.

The invention discloses a naphthalene type chalcone compound and a preparation method and application thereof, and relates to the technical field of medicinal chemistry, and the structural formula of the naphthalene type chalcone compound is shown in the specification. Wherein part of the compounds have a good inhibition effect on HDAC6 protein, can obviously inhibit proliferation of tumor cells, and can be used for developing tumor treatment drugs related to abnormal expression of HDAC6 activity.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4"-beta-D-glucoside, and combinations thereof, and an aromatic ingredient selected from the group consisting of 4-hydroxy-2H-furan-5-one, ethyl furanone, maltol, furfural, 5-methylfurfural, vanillin, benzaldehyde, and combinations thereof.

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

The invention provides a benzophenone carbazole chalcone photoinitiator and application of the benzophenone carbazole chalcone photoinitiator. The benzophenone carbazole chalcone photoinitiator comprises a compound with a structural formula as shown in a formula (I). The benzophenone carbazolyl chalcone provided by the invention can be used as a single-component photoinitiator or can be compounded with other substances to initiate a photopolymerization reaction under visible light, and particularly has a good photoinitiation effect under long-wavelength (preferably 405-470 nm) LED light.

The invention discloses a benzimidazole modified chalcone compound, a preparation method and an anti-cancer effect of the benzimidazole modified chalcone compound. According to the invention, a chalcone structure and a benzimidazole structure are combined, a compound with relatively good anti-tumor activity is expected to be obtained, the range of the existing anti-cancer compound is widened, and the compound can be continuously optimized as a lead compound. The anti-cancer capsule has a good anti-cancer effect and meets the requirements of the field of medicines.

The invention relates to a carbon-methyltransferase (RdCMT) and an application of the carbon-methyltransferase (RdCMT) in synthesis of farrerol. RdCMT is cloned and is subjected to heterologous expression in Escherichia coli BL21 (DE3) by mining transcriptome information of Rhododendron dauricum, the generated fusion protein of which the N terminal or / and the C terminal are / is connected with tags can specifically and efficiently catalyze C-3 'and C-5' methylation of chalcone compounds naringenin chalcone to generate a double-carbon-methylation product, and the double-carbon-methylation product is spontaneously dehydrated to generate the farrerol. The invention also relates to the application of the RdCMT in a model plant Nicotiana benthamiana, and the production of the farrerol through the construction of a total synthesis path of the Nicotiana benthamiana.

The invention discloses a citric acid and licochalcone B repairing composition and application, and belongs to the technical field of medicine. According to the invention, the repair promoting potential of citric acid and the anti-inflammatory and anti-oxidation activity of licochalcone B are known, and the two natural active components with different action mechanisms are creatively compounded according to a specific proportion; therefore, the citric acid and licochalcone B repairing composition which has a synergistic effect on repairing gastric mucosa epithelial cell injury caused by HP infection is provided, the effect is better than that of a single component, safety and compliance are better, and a new technical approach is provided for solving the repairing problem of clinical gastric mucosa injury.

The invention discloses a modification method of polytetrafluoroethylene, and belongs to the technical field of modification. The invention relates to a modification method of polytetrafluoroethylene, which comprises the following steps: mixing materials containing polytetrafluoroethylene, a modifier, a metal A, a metal salt and a solvent to obtain modified polytetrafluoroethylene, the modifier is a ketone compound; the ketone compound comprises a benzophenone compound and / or a chalcone compound. The method is simple to operate and high in feasibility, and polytetrafluoroethylene can be uniformly modified only by mixing the benzophenone compound (chalcone compound), the metal A, the metal salt and polytetrafluoroethylene; according to the method, the modification efficiency is high, polytetrafluoroethylene, a benzophenone compound (chalcone compound), metal A and metal salt are mixed according to the molar ratio of 0.5: 1: 1: 1, and the modification rate within 30 min can reach 100%; the modification method is novel, and the obtained polytetrafluoroethylene is uniform in modification effect.

The invention discloses a chalcone emulsion in water, application of the chalcone emulsion in water in resisting cotton verticillium wilt and a prevention and treatment method. The chalcone emulsion in water comprises the following components in percentage by mass: 25% of chalcone, 30% of solvent oil 150, 7-8% of pesticide emulsifier 600 and 0.1% of xanthan gum. The preferable formula of the 25% chalcone emulsion in water is obtained through screening, and indoor and field bacteriostasis tests prove that the 25% chalcone emulsion in water can inhibit the growth of verticillium dahliae, reduce the disease index of cotton wilt and verticillium wilt, reduce the influence of cotton wilt and verticillium wilt on the agronomic traits of cotton plants in the boll period, and improve the cotton boll period. The composition is used for preventing and treating cotton verticillium wilt or cotton blight and verticillium wilt, and the prevention and treatment method is simple and effective.

The invention provides a benzophenone carbazolyl chalcone photoinitiator and an application of the benzophenone carbazolyl chalcone photoinitiator. The benzophenone carbazolyl chalcone photoinitiator comprises a compound with a structural formula as shown in a formula (I). The benzophenone carbazolyl chalcone provided by the invention can be used as a single-component photoinitiator or can be compounded with other substances to initiate a photopolymerization reaction under visible light, and particularly has a good photoinitiation effect under long-wavelength (preferably 405-470 nm) LED light.

This invention specifically discloses a novel chalcone compound, its preparation method, pharmaceutical composition, and applications. Experimental results show that this compound exhibits significant anti-inflammatory activity in a lipopolysaccharide-stimulated RAW 264.7 cell model, significantly superior to the positive control drug dexamethasone; and in a free fatty acid-treated HepG2 cell model, it exhibits significant inhibition of lipid accumulation, significantly superior to the positive control drug obeticholic acid. It can be used to develop drugs for the treatment of non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis, and related cirrhosis.

This application discloses the application and pharmaceutical properties of glycyrrhizin chalcone A, belonging to the field of biomedical technology. The technical solution is as follows: the application of glycyrrhizin chalcone A in the preparation of anti-MS drugs. In the case that the prior art clearly shows that glycyrrhizin chalcone A has no inhibitory ability against Gram-negative bacteria, this application unexpectedly discovered that it exhibits inhibitory ability against mycoplasma, which belongs to the same genus of Gram-negative bacteria. Furthermore, the in vitro experiments of this application demonstrate that LCA has low minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against MS standard strains and clinical isolates, and has good activity.

The invention relates to an improved process for the preparation of substituted chalcones using a base that plays double role in the process, as it removes free water and catalyzes aldol condensation. Consequently, the process is cost efficient and is easily scalable to industrial level. The substituted chalcones are useful intermediates in the synthesis of isoxazolines such as Fluralaner, Afoxolaner and Sarolaner, which are known systemic insecticides and acaricides.

The present invention provides methods of generating diverse chemical structures on DNA through Wittig olefination of novel on-DNA phosphorane ylides and Homer-Wadsworth-Emmons reaction of on-DNA β-keto phosphonates. The methods of this invention provide access to DNA-encode libraries (DELs) of diverse peptides, peptidomimetics, chalcone-based molecules, and the like.

The invention belongs to the technical field of active component and target screening, and relates to a purple sweet potato leaf uric acid reducing active component and a potential target and a screening method thereof, the active component comprises rhododendron yellow, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, apigenin, quercetin glycoside, 6-hydroxycoumarin, 6, 6-dihydroxycoumarin, 3, 4, 2', 4 ', 6'-pentahydroxychalcone, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, 3, 4, 2', 4 '-pentahydroxychalcone, the component A is prepared from 2, 7-dihydroxy coumarin, daphnetin, trigonelline, serotonin, salidroside, sesamin and nicotinamide; the potential target spots comprise INS, PPAR-gamma, IL1-beta, PPAR-alpha, XDH and ABCG2; the method comprises the following steps: preparing purple sweet potato leaves and a sweet potato leaf water extract, determining the uric acid generation inhibition activity of the purple sweet potato leaves through an in-vitro experiment, and carrying out differential metabonomics combined network pharmacology analysis to excavate functional substances for reducing uric acid in the purple sweet potato leaves, thereby providing a material basis for high-valued utilization of the purple sweet potato leaves and development of functional foods for reducing uric acid.

This invention discloses a naphthyl chalcone compound, its preparation method, and its application, relating to the field of medicinal chemistry. The structural formula of the naphthyl chalcone compound is shown below. This invention utilizes computer-aided drug design to obtain a series of naphthyl chalcone compounds, some of which exhibit good inhibitory effects on HDAC6 protein and can significantly inhibit the proliferation of tumor cells. These compounds can be used to develop tumor therapeutic drugs related to abnormal expression of HDAC6 activity.

The invention relates to a nanofiber dressing with antibacterial and antioxidant functions and a preparation method of the nanofiber dressing. A natural compound isobavachalcone is loaded in a gelatin / polycaprolactone nanofiber matrix. The wound dressing can effectively inhibit growth of microorganisms, has antioxidant activity and is beneficial to promoting wound healing. The invention also relates to a method for preparing the nanofiber wound dressing.

The invention provides application of a chalcone compound as well as a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicament for treating depression. The depression is selected from mild depression, moderate depression, severe depression, persistent depressive disorder, depression associated with bipolar disorder, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual anxiety disorder, encountering depression, pleasant sensation deficiency, melancholia, middle-year depression and late-year depression; depression caused by identifiable pressure factors, refractory depression, or a combination thereof. The compounds can treat mental symptoms of depression, such as depressive mood and loss of interest or fun in almost all activities.

This invention relates to a pyrrolidinyl bifunctional catalyst linked to a photosensitizer, its preparation method, and its application. The catalyst possesses a nitrogen-tetradentate chiral center and a thioxanthone photosensitizing structural unit. In the preparation method, a chiral tetradentate ligand is chemically linked to a photosensitizer, followed by complexation with a metal salt to obtain a metal complex catalyst with both a chiral catalytic center and a photocatalytic center. This catalyst is applied to the asymmetric epoxidation reaction of chalcone, developing an asymmetric epoxidation process using oxygen as the oxidant. This invention is environmentally friendly and exhibits high stereoselectivity.

The application relates to a kind of chalcone structure-containing isopropanolamine compounds and a preparation method and application thereof.The compound has the structure as shown in general formula (I):The application introduces nitrogen-containing fragment into the system based on chalcone compounds, and synthesizes a series of chalcone isopropanolamine compounds, and the compound has good inhibitory effect on plant pathogenic bacteria and plant pathogenic fungi.

The invention discloses preparation and application of a novel chalcone compound extracted from motherwort herb, and belongs to the field of environmental governance. The molecular formula of the compound is C22H22O5cy, and the structural formula of the compound is shown in the specification. The preparation method of the novel chalcone compound (I) comprises the following steps: crushing collected motherwort leaves and stems, soaking, extracting and concentrating into an extract a; extracting the extract a, and concentrating under reduced pressure to obtain extract b; and carrying out silica gel column chromatography on the extract b, collecting an eluent in sections, carrying out thin-layer chromatography detection, combining parts with the same polarity, and carrying out NMR (nuclear magnetic resonance) identification on the structure. The preparation method has the advantages of easily available raw materials, simple extraction and easy separation; the compound is simple in structure and has conditions for realizing subsequent industrial production; the novel chalcone compound (I) shows good antibacterial activity, can effectively inhibit growth of escherichia coli, bacillus subtilis, pseudomonas aeruginosa and staphylococcus aureus, and can be used for development of antibacterial agents in deodorization products.